Download this measure in English. BACK FACIT-SWiP English Downloads Download PDF Download DOC

OMDQ Oral Mucositis Daily Questionniare A daily measure for patients with oral mucositis LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Originally developed by Amgen in conjunction with clinical studies in support of palifermin, the OMDQ is a reliable, valid, and responsive patient-reported measure of oral mucositis severity. While multiple variants of the OMDQ/OMWQ have been published, the version licensed by FACIT.org is the official, final version developed by Amgen. MEASURE NAME: Oral Mucositis Daily Questionniare (OMDQ) VERSION: 2 NUMBER OF ITEMS: 5 PATIENT POPULATION: Oral mucositis patients 18 years and older RECALL PERIOD: Past 24 hours RESPONSE SCALE: Various DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Not available TIME FOR COMPLETION: Not available SCORING: Manual scoring template RELATED MEASURES: OMWQ , FACT-HN , NFHNSI-22 DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the OMDQ can be obtained when licensing the measure. Users are not permitted to translate the OMDQ without prior permission from FACIT.org. Permission may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor of the OMDQ. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Stiff PJ, Erder H, Bensinger WI, Emmanouilides C, Gentile T, Isitt J, Lu ZJ, Spielberger R. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006 Feb;37(4):393-401. doi: 10.1038/sj.bmt.1705250. PMID: 16415901. LICENSE THIS MEASURE Related Measures Related Measures OMWQ Oral Mucositis Weekly Questionnaire LEARN MORE FACT-HN Functional Assessment of Cancer Therapy – Head and Neck LEARN MORE NFHNSI-22 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index - 22 Item Version LEARN MORE

View all available languages for this measure. BACK NFCSI-19 Languages English Hebrew Romanian Spanish

CCSQ Chemotherapy Convenience and Satisfaction Questionnaire LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Chemotherapy Convenience and Satisfaction Questionnaire (CCSQ) is comprised of two versions. The first is administered prior to initiating therapy and captures patients’ expectations on two domains: Chemotherapy Concerns (5 items) and Chemotherapy Convenience (3 items). The second version is administered while patients are on therapy (i.e., all post- Baseline Assessments) and includes three domains: Chemotherapy Concerns (5 items), Chemotherapy Convenience (3 items), and Chemotherapy Satisfaction (4 items). While its validity has been explored in multiple clinical trials, research into the relationship between the subscale scores and clinical variables should be explored in the future to further establish the measure’s validity. MEASURE NAME: Chemotherapy Convenience and Satisfaction Questionnaire (CCSQ) VERSION: 3 - Baseline 6 - On Therapy NUMBER OF ITEMS: 11 - Baseline 15 - On Therapy + Resource Utilization PATIENT POPULATION: Cancer patients 18 years and older receiving chemotherapy RECALL PERIOD: None RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Baseline: Chemotherapy Concerns, Chemotherapy Convenience On Therapy: Chemotherapy Concerns, Chemotherapy Convenience, Chemotherapy Satisfaction TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template. Subscale scores and total scores possible. Not all items are included in the total score - see scoring template for details. RELATED MEASURES: FACIT-TS-G , FACIT-TS-PS , FACT-Cog DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the CCSQ can be obtained by registering for permission. Users are not permitted to translate the CCSQ without permission from FACIT.org. Permission from FACIT.org to translate the CCSQ may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Yost K., Hahn E., Cella D. A new measure of chemotherapy convenience and satisfaction: the CCSQ. Journal of Clinical Oncology 2005; 23:538a. Saltz L., Badarinath S., Dakhil S., Bienvenu B., Harker W.G., Birchfield G., Tokaz L.K., Barrera D., Conkling P.R., O'Rourke M.A., Richards D.A., Reidy D., Solit D., Vakiani E., Capanu M., Scales A., Zhan F., Boehm K.A., Asmar L., Cohn A. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clinical Colorectal Cancer 2012; Jun 11(2):101-11. Chua D.T., Yiu H.H., Seetalarom K., Ng A.W., Kurnianda J., Shotelersuk K., Krishnan G., Hong R.L., Yang M.H., Wang C.H., Sze W.K., Ng W.T. Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. Head & Neck 2012; Sep 34(9):1225-30. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-TS-G Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction – General LEARN MORE FACIT-TS-PS Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - Patient Satisfaction LEARN MORE FACT-Cog Functional Assessment of Cancer Therapy - Cognitive Function LEARN MORE

Download scoring documents for this measure. BACK FACT-V Scoring Downloads Download DOC

View all available languages for this measure. BACK FBSI Languages Afrikaans Arabic Armenian Bengali Bosnian Bulgarian Burmese Cebuano Chinese - Simplified Chinese - Traditional Croatian Czech Danish Dutch English Estonian Farsi Finnish French German Greek Gujarati Haitian Creole Hebrew Hindi Hungarian Indonesian Italian Japanese Kannada Korean Latvian Lithuanian Macedonian Malay Malayalam Maltese Marathi Norwegian Polish Portuguese Punjabi Romanian Russian Sepedi Serbian Slovak Slovene Spanish Swedish Tagalog Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Wolof Xhosa Zulu

FACT-RNT Functional Assessment of Cancer Therapy – Radionuclide Therapy For patients receiving radionuclide therapy LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) is a standardized measure to monitor relevant symptoms and toxicities among prostate cancer patients in RNT trials and clinical settings. It was developed first by identifying relevant symptoms and toxicities by reviewing published trials and interviewing prostate cancer patients receiving radionuclide therapy (n=529), caregivers (n=514), and clinicians (n=511), then by selecting items for inclusion. The item list was refined with input from experts in RNTs and patient reported outcomes measures. MEASURE NAME: Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) VERSION: 1 NUMBER OF ITEMS: 15 PATIENT POPULATION: Patients receiving radionuclide therapy (RNT) for prostate cancer aged 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: RNT TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, total score possible. RELATED MEASURES: FACT-P , NFPSI-17 , FPSI DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-RNT can be obtained by registering for permission. Users are not permitted to translate the FACT-RNT without permission from FACIT.org. Permission from FACIT.org to translate the FACT-RNT may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Gudenkauf LM, Chavez M, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. J Nucl Med. 2023 Jan 12:jnumed.122.264946. doi: 10.2967/jnumed.122.264946. Epub ahead of print. PMID: 36635088. LICENSE THIS MEASURE Related Measures Related Measures FACT-P Functional Assessment of Cancer Therapy – Prostate LEARN MORE NFPSI-17 NCCN/FACT Prostate Cancer Symptom Index - 17 Item Version LEARN MORE FPSI FACT Prostate Cancer Symptom Index - 7 Item Version LEARN MORE

View all available languages for this measure. BACK FPSI Languages Arabic Bulgarian Chinese - Simplified Chinese - Traditional Czech Danish Dutch English Finnish French German Hebrew Hungarian Italian Japanese Korean Norwegian Polish Portuguese Russian Spanish Swedish

FKSI-10 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version For patients with Kidney Cancer, a 10 item scale LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FKSI-10 measure: MEASURE NAME: Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 10 Item Version (FKSI-10) VERSION: 4 NUMBER OF ITEMS: 10 PATIENT POPULATION: Kidney cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Kidney cancer symptom index TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores available. RELATED MEASURES: FKSI-15 , NFKSI-19 , FKSI-DRS DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FKSI-10 can be obtained by registering for permission. Users are not permitted to translate the FKSI-10 without permission from FACIT.org. Permission from FACIT.org to translate the FKSI-10 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Bukowski, R., Cella, D., Gondek, K., Escudier, B. Effects of sorafenib on symptoms and quality of life results from a large randomized placebo-controlled study in renal cancer. American Journal of Clinical Oncology; 2007: 30(3): 220-227. doi: 10.1097/01.coc.0000258732.80710.05. Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Yount, S., Du, H., Dhanda, R., Gondek, K., Langefeld, K., George, J., Bro, W., Kelly, C., & Bukowski, R. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). Journal of Supportive Oncology 2006; 4(4):191-199. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FKSI-15 Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 15 Item Version LEARN MORE NFKSI-19 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - 19 Item Version LEARN MORE FKSI-DRS Functional Assessment of Cancer Therapy Kidney Cancer Symptom Index - Disease Related Symptoms LEARN MORE

Download scoring documents for this measure. BACK FAMS Scoring Downloads Download DOC

FAMS Functional Assessment of Multiple Sclerosis LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the FAMS measure: MEASURE NAME: Functional Assessment of Multiple Sclerosis (FAMS) VERSION: 4 NUMBER OF ITEMS: 58 PATIENT POPULATION: Multiple sclerosis patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Mobility, Symptoms, Emotional Well-Being, General Contentment, Thinking and Fatigue, Family/Social Well-Being, Additional Concerns TIME FOR COMPLETION: 15-20 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. SAS/SPSS algorithms available. RELATED MEASURES: FAHI , FACIT-Dyspnea , FACIT-TB DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FAMS can be obtained by registering for permission. Users are not permitted to translate the FAMS without permission from FACIT.org. Permission from FACIT.org to translate the FAMS may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D.F., Dineen, K., Arnason, B., Reder, A., Webster, K.A., Karabatsos, G., Chang, C., Lloyd, S., Mo, F., Stewart, J., & Stefoski, D. Validation of the Functional Assessment of Multiple Sclerosis Quality of life instrument. Neurology 1996; 47: 129-139. doi: 10.1212/WNL.47.1.129. Fischer, J., LaRocca, N., Miller, D., Ritvo, P., Andrews, H. & Paty, D. Recent developments in the assessment of quality of life in Multiple Sclerosis (MS). Multiple Sclerosis 1999; 5(4): 251-259. doi: 10.1177/135245859900500410. Kossakowska, M. Standaryzacja polskiej wersji Kwestionariusza do Oceny Jakości Życia w Stwardnieniu Rozsianym (FAMS). Psychologia Jakości Życia , 2004; 3(1): 61-80. Riazi, A., Hobart, J., Lamping, D., Fitzpatrick, R., & Thompson, A. Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales. Multiple Sclerosis 2003; 9; 411-419. doi: 10.1191/1352458503ms929oa. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FAHI Functional Assessment of HIV Infection LEARN MORE FACIT-Dyspnea Functional Assessment of Chronic Illness Therapy - Dyspnea-10 item LEARN MORE FACIT-TB Functional Assessment of Chronic Illness Therapy - Tuberculosis LEARN MORE

PROMIS Pool v1.0 - Dyspnea Emotional Response Patient Reported Outcomes Measurement Information System Pool - Dyspnea Emotional Response For patients with dyspnea LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details on the PROMIS Pool v1.0 - Dyspnea Emotional Response MEASURE NAME: PROMIS Pool v1.0 - Dyspnea Emotional Response VERSION: 1 NUMBER OF ITEMS: 7 PATIENT POPULATION: Dyspnea patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic For permission to implement and administer the measure electronically, please visit: https://www.healthmeasures.net/implement-healthmeasures/administration-platforms ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Dyspnea Emotional Response TIME FOR COMPLETION: Less than 5 minutes SCORING: PROMIS Scoring Service: http://www.healthmeasures.net/score-and-interpret/calculate-scores/scoring-instructions RELATED MEASURES: FACIT-Dyspnea , PROMIS Pool v1.0 - Dyspnea Task Avoidance , PROMIS Pool v1.0 - Dyspnea Time Extension DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the PROMIS Pool v1.0 - Dyspnea Emotional Response can be obtained by registering for permission. Users are not permitted to translate the PROMIS Pool v1.0 - Dyspnea Emotional Response without permission from FACIT.org. Permission from FACIT.org to translate the PROMIS Pool v1.0 - Dyspnea Emotional Response may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Choi, S., Victorson, D., Yount, S., Anton, S., & Cella, D. Development of a conceptual framework and calibrated item banks to measure patient reported dyspnea severity and related functional limitations. Value in Health 2011; 14: 291-306. Ruo, B., Choi, S., Baker, D., Grady, K., & Cella,D. Development and validation of a computer adaptive test measuring dyspnea in heart failure. Journal of Cardiac Failure 2010; 16(8): 659-668. doi: 10.1016/j.cardfail.2010.03.002. Victorson, D., Anton, S., Hamilton, A., Yount, S., & Cella, D. A conceptual model of the experience of dyspnea and functional limitations in COPD. Value in Health 2009; 12(6): 1018-1025. Yount, S., Choi, S., Victorson, D., Ruo, B., Ray, D., Cella, D., Anton, S., & Hamilton, A. (2011) Brief, valid measures of dyspnea and related functional limitations in chronic obstructive pulmonary disease (COPD). Value in Health 2011; 14: 307-315. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACIT-Dyspnea Functional Assessment of Chronic Illness Therapy - Dyspnea-10 item LEARN MORE PROMIS Pool v1.0 - Dyspnea Task Avoidance Patient-Reported Outcomes Measurement Information System Pool - Dyspnea Task Avoidance LEARN MORE PROMIS Pool v1.0 - Dyspnea Time Extension Patient-Reported Outcomes Measurement Information System Pool - Dyspnea Time Extension LEARN MORE